Proviron is an oral androgen and anabolic steroid (AAS) drug developed in the 1960s and introduced for medical use by Schering in 1967 . It is a derivative of DHT, does not produce estrogen, has weak androgenic and anabolic effects, is used primarily to treat low testosterone levels, and has also been used to treat male infertility.
Product Name: Proviron
Other name: Mesterolone
CAS : 1424-00-6
Appearance: White powder
Package: 10g/bag or as customers'request.
Test Method: HPLC
Proviron is an androgen receptor (AR) agonist and has relatively low androgen and anabolic potency due to the inactivation of 3α-hydroxy steroid dehydrogenase (3α-HSD) in skeletal muscle tissue, similar to DHT and Proviron . However, it still shows a greater ratio of anabolic activity to androgen activity compared to testosterone.
Proviron is not a substrate for 5α-reductase because it has been reduced by 5α-reductase. Therefore, there is no enhancement in androgenic tissues such as skin, hair follicles, and prostate.
Proviron is not a substrate for aromatase and cannot be converted to estrogen. As a result, Proviron is not associated with estrogen side effects, such as gynecomastia and fluid retention.
Proviron is not a 17α-alkyl compound, so it has little hepatotoxicity.
Proviron is not metabolized by the liver and has significant oral activity. It is one of the few oral AAS that are either 17 alpha-alkylated or not. Proviron can be used in high doses or for longer periods of time depending on the individual situation.
Proviron has a very high affinity for human serum sex hormone binding protein (SHBG), and therefore, it may replace endogenous testosterone in binding to SHBG, thereby increasing serum free testosterone concentration. Similarly, when Proviron is preferentially combined with SHBG, the activities of other AAS can be increased to make other AAS play their full role.